Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Karyopharm Therapeutics Inc. | d934067dex991.htm |
| EX-99.2 - EX-99.2 - Karyopharm Therapeutics Inc. | d934067dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 30, 2015
Karyopharm Therapeutics Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-36167 | 26-3931704 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 85 Wells Avenue, 2nd Floor, Newton, Massachusetts |
02459 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (617) 658-0600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events |
On May 30, 2015 and June 1, 2015, Karyopharm Therapeutics Inc. issued press releases announcing new data for its lead product candidate, selinexor (KPT-330). A copy of each press release is filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
The exhibits to this Current Report on Form 8-K are listed in the Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KARYOPHARM THERAPEUTICS INC. | ||||||
| Date: June 1, 2015 | By: | /s/ Christopher B. Primiano | ||||
| Christopher B. Primiano | ||||||
| Vice President, Corporate Development, | ||||||
| General Counsel and Secretary | ||||||
EXHIBIT INDEX
| Exhibit |
Description | |
| 99.1 | Press release dated May 30, 2015, entitled Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients with Heavily Pretreated Gynecological Cancers and Asian Patients with Advanced Malignancies at 2015 ASCO Annual Meeting. | |
| 99.2 | Press release dated June 1, 2015, entitled Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients with Recurrent Glioblastoma and Advanced Sarcomas at 2015 ASCO Annual Meeting. | |